Further studies employing CRISPR knockdown of HAS3 (and other top genes) are needed to further explore the significance of these novel mechanisms and their impact on cancer stemness and its association with METRO-TOPO treatment-related efficacy. This evidence concerns the gene HAS3 and cancer.